The use of herbal and over-the-counter dietary supplements for the prevention of prostate cancer

Current Urology Reports

Volumn 7, Issue 3, 2006, Pages 166-174

  Bemis, Debra L ^b   Capodice, Jillian L ^b   Costello, Jennifer E ^b   Vorys, George C ^b   Katz, Aaron E ^b   Buttyan, Ralph ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CATECHIN; COLECALCIFEROL; CURCUMIN; ERGOCALCIFEROL; GREEN TEA EXTRACT; HERBACEOUS AGENT; ISOFLAVONE DERIVATIVE; LYCOPENE; NON PRESCRIPTION DRUG; PLANT EXTRACT; PYGEUM AFRICANUM EXTRACT; RESVERATROL; SABAL EXTRACT; SELENIUM; SILYBUM MARIANUM EXTRACT; URTICA DIOICA EXTRACT; VITAMIN; VITAMIN D;

CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DIET SUPPLEMENTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PROSTATE CANCER; REVIEW;

ANTICARCINOGENIC AGENTS; CAROTENOIDS; CATECHIN; DIETARY SUPPLEMENTS; DRUGS, NON-PRESCRIPTION; HUMANS; MALE; PHYTOTHERAPY; PLANT PREPARATIONS; PROSTATIC NEOPLASMS;

EID: 33750333236     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-006-0017-x     Document Type: Review

References (91)

1. American Cancer Society: Cancer facts and figures, 2005. http://www.cancer.org.
2. Hsieh K, Albertsen PC: Populations at high risk for prostate cancer. Urol Clin North Am 2003, 30:669-676. Good discussion of general risk factors for prostate cancer.
3. Flanders WD: Review: prostate cancer epidemiology. Prostate 1984, 5:621-629.
4. Crawford ED: Epidemiology of prostate cancer. Urology 2003, 167:3-12. Another nice review of prostate cancer epidemiology.
5. Yip I, Heber D, Aronson W: Nutrition and prostate cancer. Urol Clin North Am 1999, 26:403-411.
6. Clinton SK, Giovannucci E: Diet, nutrition and prostate cancer. Annu Rev Nutr 1998, 18:413-440.
7. Sim HG, Cheng CW: Changing demography of prostate cancer in Asia. Eur J Cancer 2005:834-845. Discusses the increasing trend of prostate cancer occurrence in Asian countries.
8. Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. New Engl J Med 2003, 349:215-224.
9. Dvorkin L, Song KY: Herbs for benign prostatic hyperplasia. Ann Pharmacother 2002, 36:1443-1452.
10. Konrad L, Muller HH, Lenz C, et al.: Antiproliferative effect on human prostate cancer cells by stinging nettle root (Urtica dioica) extract. Planta Medica 2000, 66:44-47.
11. Goldmann WH, Sharma AL, Currier SJ, et al.: Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol Int 2001, 25:1117-1124.
12. Hill B, Kyprianou N: Effect of permixon on human prostate cell growth: lack of apoptotic action. Prostate 2004, 61:73-80.
13. Davis-Searles PR, Nakanishi Y, Kim NC, et al.: Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 2005, 65:4484-4457.
14. Singh RP, Agarwal R: A cancer chemopreventative agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat Res 2004, 555:21-32.
15. Singh RP, Sharma G, Dhanalakshmi S, et al.: Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003, 12:933-939.
16. Tyagi A, Agarwal C, Agarwal R: The cancer preventative flavonoid silibinin causes hypophosphorylation of Rb/p107 and Rb2/p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells. Cell Cycle 2002, 1:137-142.
17. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R: Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene 2002, 21:1759-1767.
18. Jarred RA, Keikha M, Dowling C, et al.: Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 2002, 11:1689-1696.
19. Clinton S: Lycopene: chemistry, biology and implications for human health and disease. Nutr Rev 1998, 56:35-51.
20. Stahl W, Schwarz W, Sundquist AR, Sies H: Cis-trans isomers of lycopene and beta carotene in human serum and tissues. Arch Biochem Biophys, 1992, 294:173-177.
21. Giovannucci E, Ascherio A, Rimm EB, et al.: Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995, 87:1767-1776.
22. Giovannucci E: Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr 2005, 135:2030-2031. Excellent recent review of evidence supporting a role for lycopene as a prostate cancer preventative.
23. Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al.: Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001, 93:1872-1879.
24. Tang L, Jin T, Zeng X, Wang JS: Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in BALB/c nude mice. J Nutr 2005, 135:287-290.
25. Hantz HL, Young LF, Martin KR: Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp Biol Med 2005, 230:171-179.
26. Herzog A, Siler U, Spitzer V, et al.: Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 2005, 19:272-274.
27. Gann PH, Ma J, Giovannucci E, et al.: Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999, 59:1225-1230.
28. Nomura AM, Stemmermann GN, Lee J, Craft NE: Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. Cancer Epidemiol Biomarkers Prev 1997, 6:487-491.
29. Greenwald P: Clinical trials in cancer prevention: Current results and perspectives for the future. J Nutr 2004, 134:3507-3512. General discussion of ongoing prevention trials involving food derived substances.
30. Schneider C: Chemistry and biology of vitamin E. Mol Nutr Food Res 2005, 49:7-30. Good review of vitamin E and its effects.
31. Traber MG, Arai H: Molecular mechanisms of vitamin E transport. Annu Rev Nutr 1999, 19:343-355.
32. Heinonen OP, Albanes D, Virtamo J, et al.: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90:440-446.
33. Traber MG, Packer L: Vitamin E: beyond antioxidant function. Am J Clin Nutr 1995, 62:1501S-1509S.
34. Nelson WG, DeWeese TL, DeMarzo AM: The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002, 21:3-16. Excellent discussion of the potential role of inflammation in prostate cancer.
35. Gunawardena K, Murray DK, Meikle AW: Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. Prostate 2000, 44:287-295.
36. Venkateswaran V, Fleshner NE, Klotz LH: Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol 2002, 168:1578-1582.
37. Fleshner N, Fair WR, Huryk R, Heston WD: Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol 1999, 161:1651-1654.
38. Grant WB, Holick MF: Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 2005, 10:94-111.
39. Schwartz GG, Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990, 10:1307-1311.
40. Giovannucci E: Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 1998, 9:567-582.
41. Chen TC, Holick MF: Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 2003, 14:423-430.
42. Krishnan AV, Peehl DM, Feldman D: Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem 2003, 88:363-371.
43. Peehl DM, Krishnan AV, Feldman D: Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 2003, 133(suppl 7):2461S-2469S.
44. Zhao XY, Ly LH, Peehl DM, Feldman D: Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999, 140:1205-1212.
45. Kim YS, Milner J: Molecular targets for selenium in cancer prevention. Nutr Cancer 2001, 40:50-54.
46. Clark LC, Combs GF, Turnbull BW, et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996, 276:1957-1963.
47. Brooks JD, Metter EJ, Chan DW, et al.: Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001, 166:2034-2038.
48. Vogt TM, Ziegler RG, Graubard BI, et al.: Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Cancer 2003, 103:664-670.
49. Allen NE, Morris JS, Ngwenyama RA, Key TJ: A case-control study of selenium in nails and prostate cancer risk in British men. Br J Cancer 2004, 90:1392-1396.
50. Yamaguchi K, Uzzo RG, Pimkina J, et al.: Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 2005, 24:5868-5877.
51. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C: Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 2003, 63:52-59.
52. Corcoran NM, Najdovska M, Costello AJ: Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 2004, 171:907-910.
53. Lee MM, Gomez SL, Chang JS, et al.: Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 2003, 12:665-668.
54. Holzbeierlein JM, McIntosh J, Thrasher JB: The role of soy phytoestrogens in prostate cancer. Curr Opin Urol 2005, 15:17-22. Nice review of soy isoflavones and their role in prostate cancer chemoprevention.
55. Sarkar FH, Li Y: Soy isoflavones and cancer progression. Cancer Invest 2003, 21:744-757.
56. Akiyama T, Ishida J, Nakagawa S, et al.: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987, 262:5592-5595.
57. Constantinou A, Mehta R, Runyan C, et al.: Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J Nat Prod 1995, 58:217-225.
58. Fotsis T, Pepper M, Adlercreutz H, et al.: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993, 90:2690-2694.
59. Shen JC, Klein RD, Wei Q, et al.: Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 2000, 29:92-102.
60. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, et al.: Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr 2005, 135:989-995.
61. Hikosaka A, Asamoto M, Hokaiwado N, et al.: Inhibitory effects of soy isoflavones on rat prostate carcinogenesis induced by 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis 2004, 25:381-387.
62. Bemis DL, Capodice JL, Desai M, et al.: A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin Cancer Res 2004, 10:5282-5292.
63. Kumar NB, Cantor A, Allen K, et al.: The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004, 59:141-147. Another excellent summary of soy isoflavones and prostate cancer risk.
64. Dalais FS, Meliala A, Wattanapenpaiboon N, et al.: Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 2004, 64:510-515.
65. Spentzos D, Mantzoros C, Regan MM, et al.: Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. Clin Cancer Res 2003, 9:3282-3287.
66. Gupta S, Ahmad N, Mukhtar H: Prostate cancer chemoprevention by green tea. Semin Urol Oncol 1999, 17:70-76. Review of green tea-derived polyphenols and potential use as prostate cancer preventative.
67. Saleem M, Adhami VM, Siddiqui IA, Mukhtar H: Tea beverage in chemoprevention of prostate cancer: a mini-review. Nutr Cancer 2003, 47:13-23.
68. Ren F, Zhang S, Mitchell SH, et al.: Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 2000, 19:1924-1932.
69. Hastak K, Gupta S, Ahmad N, et al.: Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003, 22:4851-4859.
70. Hastak K, Agarwal MK, Mukhtar H, Agarwal ML: Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 2005, 19:789-791.
71. Gupta S, Hastak K, Ahmad N, et al.: Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 2001, 98:10350-10355.
72. Roomi MW, Ivanov V, Kalinovsky T, et al.: In vivo antitumor effect of ascorbic acid, lysine, proline and green tea extract on human prostate cancer PC-3 xenografts in nude mice: evaluation of tumor growth and immunohistochemistry. In Vivo 2005, 19:179-183.
73. Adhami VM, Siddiqui IA, Ahmad N, et al.: Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004, 64:8715-8722.
74. Choan E, Segal R, Jonker D, et al.: A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol 2005, 23:108-113.
75. Jatoi A, Ellison N, Burch PA, et al.: A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003, 97:1442-1446.
76. Ratan HL, Steward WP, Gescher AJ, Mellon JK: Resveratrol-a prostate cancer chemopreventive agent? Urol Oncol 2002, 7:223-227. General review on resveratrol and its potential as prostate cancer preventative.
77. Hsieh TC, Wu JM: Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 1999, 249:109-115.
78. Kim YA, Rhee SH, Park KY, Choi YH: Antiproliferative effect of resveratrol in human prostate carcinoma cells. J Med Food 2003, 6:273-280.
79. Narayanan BA, Narayanan NK, Re GG, Nixon DW: Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer 2003, 104:204-212.
80. Lin HY, Shih A, Davis FB, et al.: Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol 2002, 168:748-755.
81. Mitchell SH, Zhu W, Young CY: Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 1999, 59:5892-5895.
82. Joe B, Vijaykumar M, Lokesh BR: Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr 2004, 44:97-111. Nice, general review on curcumin and its effects on prostate cancer cells.
83. Sharma OP: Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976, 25:1811-1822.
84. Satoskar RR, Shah SJ, Shenoy SG: Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol 1986, 24:651-654.
85. Dorai T, Gehani N, Katz A: Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol 2000, 4:1-6.
86. Ohtsu H, Xiao Z, Ishida J, et al.: Curcumin analogues as novel androgen receptor antagonists with potential as antiprostate cancer agents. J Med Chem 2002, 45:5037-5042.
87. Chaudhary LR, Hruska KA: Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem 2003, 89:1-5.
88. Deeb D, Jiang H, Gao X, et al.: Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther 2004, 3:803-812.
89. Dorai T, Dutcher JP, Dempster DW, Wiernik PH: Therapeutic potential of curcumin in prostate cancer-V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate 2004, 60:1-17.
90. Dorai T, Cao YC, Dorai B, et al.: Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 2001, 47:293-303.
91. Imaida K, Tamano S, Kato K, et al.: Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis. Carcinogenesis 2001, 22:467-472.